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Abstract
This study aimed to estimate the absorption, distribution, metabolism and excretion (ADME) properties and safety of LDT5,
a lead compound for oral treatment of benign prostatic hyperplasia that has previously been characterized as a multi-target
antagonist of a1A-, a1D-adrenoceptors and 5-HT1A receptors. The preclinical characterization of this compound comprised the
evaluation of its in vitro properties, including plasma, microsomal and hepatocytes stability, cytochrome P450 metabolism and
inhibition, plasma protein binding, and permeability using MDCK-MDR1 cells. De-risking and preliminary safety pharmacology
assays were performed through screening of 44 off-target receptors and in vivo tests in mice (rota-rod and single dose toxicity).
LDT5 is stable in rat and human plasma, human liver microsomes and hepatocytes, but unstable in rat liver microsomes and
hepatocytes (half-life of 11 min). LDT5 is highly permeable across the MDCK-MDR1 monolayer (Papp B32 10-6 cm/s),
indicating good intestinal absorption and putative brain penetration. LDT5 is not extensively protein-bound and is a substrate of
human CYP2D6 and CYP2C19 but not of CYP3A4 (half-life460 min), and did not signiﬁcantly inﬂuence the activities of any of
the human cytochrome P450 isoforms screened. LDT5 was considered safe albeit new studies are necessary to rule out
putative central adverse effects through D2, 5-HT1A and 5-HT2B receptors, after chronic use. This work highlights the drug-
likeness properties of LDT5 and supports its further preclinical development.
Key words: Benign prostatic hyperplasia; ADME; Safety; Permeability; CYP; Preclinical development
Introduction
As the population ages in developed countries and
also in countries with fast-growing economies such as the
so-called BRICS, which account for around 42% of the
world population, the impact of progressive diseases is
a global concern. As such, benign prostatic hyperplasia
(BPH) has a considerable impact on the health and quality
of life of a large portion of aging men (1).
BPH is a nonmalignant progressive enlargement of the
prostate and is characterized mainly by stromal hyperplasia
in the periurethral transition zone and sympathetic autonomic
nervous system hyperactivity (2). BPH pathophysiology
involves a static component caused by prostatic enlargement
and a dynamic component due to an increased smooth
muscle contraction, and both contribute to the lower urinary
tract symptoms suggestive of BPH (LUTS/BPH). LUTS/BPH
is characterized by hesitancy, weak urinary stream, frequent
urination and urgency. Moreover, prostatic enlargement may
also be associated with discomfort, and sexual dysfunction (2).
The current drug market includes drugs to treat LUTS/
BPH, such as the classical a1-adrenoceptor blockers and
the more recently approved phosphodiesterase 5 inhibitor
(PDE5-I) tadalaﬁl, and drugs to shrink the prostate, such as
5-alpha-reductase inhibitors (5-ARI). The a1-adrenoceptor
blockers, currently recommended as ﬁrst-line therapies
for moderate to severe LUTS/BPH (3), reduce symptoms
by relaxing the prostatic smooth muscle (4). High afﬁnity
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antagonists for the a1A subtype (tamsulosin, silodosin,
alfuzosin) are generally preferred due to less postural
hypotension albeit not presenting higher efﬁcacy than the
older non-selective a1-adrenoceptor blockers terazosin and
doxazosin, which were recently pointed as the most effec-
tive drugs in a recent meta-analysis (1). It should be noted
that the selection of the most appropriate drug for treating
LUTS/BPH in older persons (465 years) could be different
(5). On the other hand, the two 5-ARI drugs approved for
prostate shrinkage (ﬁnasteride and dutasteride) exert anti-
androgenic action that may cause adverse sexual effects.
Some years ago we initiated a radical innovation pro-
gram aiming to obtain a ﬁrst-in-class drug, as a single com-
pound with efﬁcacy on both urinary symptoms and prostatic
hyperplasia (prevention/slowing of disease progression).
First, we showed that the N1-(2-methoxyphenyl)-N4-piper-
azine moiety confers afﬁnity for a1A-, a1D-adrenoceptors
and 5-HT1A receptors (6). Then, we reported that one of the
derivatives, LDT5, was a multi-target compound designed
to exert both prostatic relaxation and antiproliferative actions
in BPH through action at three different receptor targets:
antagonism at a1A-adrenoceptor providing mechanism of
action (MOA) for treating LUTS while antagonism at the
a1D-adrenoceptor and 5-HT1A receptor would provide MOA
for preventing human prostatic stromal hyperplasia (7). As a
result, such compound would have potential clinical use
either as monotherapy in ﬁrst stages of BPH or after treat-
ment, to shrink the prostate (e.g., with a 5-ARI).
In our previous paper (7), we detailed the in vitro and
in vivo pharmacodynamics properties of LDT5 that sup-
port our hypothesis of a multi-target antagonism for a dual
effect in BPH treatment. Here, we report data addressing
the drug-likeness and safety of our elected compound.
Indeed, early in vitro ADME (absorption, distribution,
metabolism and excretion) screening is essential in a
drug discovery process for verifying if a drug candidate
has desirable drug metabolism and pharmacokinetics
(PK) proﬁles that warrant further preclinical development
(8,9). At the same time, preliminary tests for de-risking a
lead compound are also required in order to decrease the
high attrition rate observed during the drug discovery and
development process (10,11). Present results indicate that
LDT5 has no safety concern and that its drug-likeness




ethyl]piperazine monohydrochloride) was synthesized and
characterized by spectroscopy as previously described (7).
Figure 1 provides the 2-D structure of LDT5 in its base form.
Animals
All experiments were conducted in compliance with
the ethical standards of the Universidade Federal do Rio
de Janeiro (licenses DFBCICB011 and DFBCICB015-04/
16) and with the recommendations of the Committee on
Care and Use of Laboratory Animals of the National
Research Council of the United States.
Physicochemical properties and drug-likeness
The molecular properties of LDT5 were calculated
using the ACD/Percepta software, version 14.0.0 (Build
2254), PhysChem module (Advanced Chemistry Devel-
opment, Inc., Canada).
In vitro ADME studies
These studies were performed at Advinus Therapeu-
tics Limited (India).
Solubility at pH 7.4
This assay was performed as part of the routine in vitro
PK assays, even knowing that LDT5 (a monohydrochlo-
ride salt) was highly water soluble. The study was
performed in a 96-deep well plate by spiking 10 mL of
working stock solutions to 990 mL of 50 mM sodium
phosphate buffer, pH 7.4. After 2 h, the plate was
centrifuged at 1,000 g for 20 min at room temperature
and aliquots were withdrawn from the supernatant and
diluted 1:1 with acetonitrile for analysis by a validated LC-
MS/MS detection method using labetalol as an internal
standard, a BDS Hypersil Phenyl (150*4.6, 5 mm) column
and a mobile phase composed of 5 mM ammonium
formate:acetonitrile (40:60, % v/v) with 0.05% formic acid.
An API 4000 mass spectrometer (Applied Biosystems/
MDS SCIEX, Canada) was used for detection in a positive
ionization mode and with the following MRM transitions:
357.4-165.2 and 329.2-162 for LDT5 and labetolol,
respectively.
Plasma protein binding and stability
Spiked human plasma was placed in the donor com-
partment and phosphate buffer in the acceptor compart-
ment of a HTDialysis 96-well apparatus (USA). The plate
was sealed and incubated at 37°C for 6 h at 60 rpm
under 5% carbon dioxide atmosphere. Diclofenac (5 mM)
was used as a positive control and its mean fraction
unbound was 0.28%. The remaining LDT5 spiked plasma
was incubated at 37°C for 6 h to assess the stability of
LDT5.
Figure 1. 2-D structure of LDT5 in its base form.
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In vitro metabolism in rat and human liver
microsomes and hepatocytes
The intrinsic clearance in rat and human liver micro-
somes (0.5 mg/mL protein) and hepatocytes (1 million cells/
mL) was conducted at 0.5 mM of LDT5, diclofenac and
cocktail of positive control (diclofenac, 7-hydroxycoumarin
and testosterone). Microsomes: LDT5 and diclofenac were
incubated along with rat (male, Sprague Dawley) and
human (mixed, Caucasian) liver microsomes (pooled, from
XenoTech, LLC, USA) and co-factor (NADPH, 2 mM).
Samples were collected up to 30 min in acetonitrile.
NADPH-free control reactions were performed in a similar
manner. Hepatocytes: LDT5 and cocktail of positive con-
trol were incubated along with rat and human hepatocytes.
Samples were collected up to 120 min in acetonitrile. The
remaining percent of compound was determined by con-
sidering peak area ratio in the 0 min sample as 100%. The
ﬁrst order decay equation was used to estimate half-life
using GraphPad Prisms software (USA).
Permeability on MDCK-MDR1
The in vitro apparent permeability was determined
across MDCK-MDR1 cell monolayer PreadyPort plate
(Readycell, Spain). The cell culture medium contained
glucose (1.8 g), HEPES (2.98 g), 10% fetal bovine serum
(50 mL), L-glutamine (5 mL), 100 U/mL; 0.1 mg/mL Pen/
Strep (5 mL) and 1X MEM non-essential amino acid
solution, added to 435 mL of Dulbecco’s modiﬁed eagle
medium. On the day of the experiment, TEER values were
measured for each well on the plate. Buffer containing
1% DMSO was added to the apical compartment (0.25 mL)
and to the basolateral compartment (0.75 mL) and placed in
an incubator maintained at 37°C and 5% CO2 for 30 min.
The bioanalysis of LDT5 and quinidine (positive control)
was performed using LC-MS/MS.
Cumulative amount of LDT5 (Q) transported at each
time point (30, 60, 90, and 129 min) was plotted as a
function of time. The slope corresponds to the rate of
appearance of test item (dQ/dt) in the receiver compart-
ment and the apparent permeability (Papp) was calculated
using the formula: Papp = (dQ/dt) / AxC0, where A=surface
area of the membrane and C0=initial concentration.
CYP proﬁling
The in vitro metabolic rate of LDT5 was determined in
the presence of puriﬁed cytochrome P450 (CYP) 1A2,
2C9, 2C19, 2D6 and 3A4 human isozymes (Cypex, UK).
The study was conducted at 0.5 mM LDT5 with 10 pM CYP
and 2 mM NADPH in phosphate buffer at 37°C in a 96-
deep well plate after pre-incubation for 10 min. LDT5 and
CYP speciﬁc probe substrates were incubated separately
along with buffer, puriﬁed CYPs and NADPH. The time-
dependent loss of the parent compound was determined
using LC-MS/MS detection for estimation of the respective
half-lives, through nonlinear regression analysis using the
ﬁrst order decay equation.
CYP inhibition
The inhibition of CYP 1A2, 2C9, 2C19, 2D6 and 3A4
isozymes by LDT5 was evaluated in human liver micro-
somes (pooled, from XenoTech, LLC) by monitoring the
production of selective metabolites following incubation
with probe substrates. For each isozyme, a CYP-speciﬁc
probe substrate was incubated along with microsomes,
1 mM NADPH and LDT5 up to 100 mM. The reaction plate
was incubated at 37°C for time periods speciﬁc to each
isozyme.
In vitro off-target receptor binding
These assays were performed at Euroﬁns Cerep-
Panlabs (France), according to the SafetyScreen 44
panel, using mainly classical competition binding assays
and enzymatic inhibition assays with human recombinant
proteins (HEK-293 cells). Experimental conditions for
each of these 44 assays are available at the Cerep
web page: http://www.cerep.fr/cerep/users/pages/catalog/
proﬁles/DetailProﬁle.asp?proﬁle=2646. Dopaminergic D2
receptor binding using rat striatum synaptosomes were
performed as previously described (12).
Preliminary safety pharmacology
Rota-rod. Swiss Webster adult male mice (around
40 g) were trained for 1 day and 1 h before the test. Only
mice that stayed at least 1 min without falling down were
selected. LDT5 (10 mg/kg) or saline were administered iv
through the orbital plexus (50 mL) of 6 mice per group.
After 3, 10, and 30 min, the number of falls during a 4-min
observation period was recorded together with the latency
for each fall.
Acute toxicity test. Six Swiss Webster female mice
(25–30 g) per condition received a single dose (100 mg/kg,
ip) of LDT5. During the ﬁrst hour and 2, 4, and 8 h after
administration as well as daily until the 14th day, different
parameters were observed according to the method de-
scribed earlier (13). The body temperature was registered
by an anal probe before, and 30 and 60 min after drug
administration.
Results
Physicochemical properties and drug likeness
In order to assess the drug likeness of our lead
compound LDT5, we ﬁrst describe its in silico ADME
proﬁle, a step that is classically performed early, for hit-to-
lead progression (14). As shown in Table 1 (15–19), LDT5
met all the criteria of the rule of ﬁve as well as the target
values for polar surface area and number of rotatable
bonds. These two properties reﬂect the ability to permeate
cells and the conformational ﬂexibility of a molecule,
respectively (18). This table also includes two ligand
efﬁciency metrics (LE and LipE) for the three target
receptors of LDT5. The values of lipophilic efﬁciency
(LipE) within the target values (15) are important since
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this parameter sets consistent expectations for ligand
efﬁciency regardless of molecular weight or relative
potency (16).
In vitro ADME studies
LDT5 was soluble up to 100 mM, the highest con-
centration tested, in sodium phosphate buffer, pH 7.4.
As assessed by equilibrium dialysis, binding of LDT5 to
plasma proteins was intermediate at 10 mM [means±SD
values were 80±2 and 73±1% (n=6) in rat and human
plasma, respectively].
The in vitro apparent permeability of LDT5 was deter-
mined across MDCK-MDR1 cell monolayer, using LC-MS/
MS analysis of the samples. Our results indicated that
LDT5 is highly permeable (Papp=32.2±1.110–6 cm/s)
for apical to basolateral transport and (Papp=32.4±
1.110–6 cm/s) for the reverse transport (n=3). Moreover,
LDT5 is not a substrate of glycoprotein P (P-gp) (efﬂux
ratio=1) contrary to quinidine (efﬂux ratio=197.5) Papp=
0.19±0.05 10–6 cm/s for apical to basolateral transport
and 39.5±2.8 10–6 cm/s for the reverse transport (n=3),
used as a classical substrate of P-gp for indication of proper
functioning of MDCK-MDR1 cells and monolayer integrity.
LDT5 was stable in rat and human plasma at 37°C with
recovery of 87±4 and 91±4% (n=6), respectively, after
6 h incubation.
The intrinsic clearance of LDT5 in rat and human was
estimated in vitro using liver microsomes and hepato-
cytes. The concentration of LDT5 used in these assays
(0.5 mM) was chosen according to the typically low
concentrations (1–5 mM) of test compound used for
incubation to ensure the linearity of enzymatic reac-
tion, but higher than its putative clinically relevant con-
centration since it is 250–2500 times higher than
the afﬁnity for its main target receptors (7). From these
data (Figure 2), we can conclude that LDT5 is stable in
human liver microsomes (half-life 430 min; intrinsic
clearance o0.6 mL min–1  g liver–1) and hepatocytes
(half-life 120 min; intrinsic clearance o0.2; 0.22 mL 
min–1  g liver–1). On the other hand, LDT5 is unstable in
rat liver microsomes (half-life of 10 min; intrinsic clearance =
6.4; 6.7 mL min–1  g liver–1) and hepatocytes (half-life of
11 min; intrinsic clearance 42 mL min–1  g liver–1).
We then investigated the involvement of CYPs in the
metabolism of LDT5, using the human CYP1A2, 2C9,
2C19, 2D6 and 3A4 isozymes. To summarize our results
(Table 2), LDT5 was found to be a substrate of CYP2D6
with a half-life of 5 min and CYP2C19 with a half-life of
20 min. In all other tested CYPs, including CYP3A4, the
half-life was greater than 60 min.
As early assessment of putative drug-drug interac-
tion through CYP inhibition is becoming routine in drug
development projects, we estimated the capacity of
LDT5 to inhibit the main important CYP450 isoforms
(1A2, 2C9, 2C19, 2D6 and 3A4) in human liver micro-
somes (Table 3). The IC50 values for LDT5 against ﬁve
CYP isozymes were greater than the highest concentra-
tion assessed in this assay (100 mM). As a conclusion,
LDT5 is not an inhibitor of tested CYPs under these
experimental conditions.
Table 1. In silico ADME and ligand efﬁciency parameters for LDT5.
Property LDT5 Target values
ADME
MW (Da) 356.46 p500*
cLogP 3.45 p5*
cLogD (pH 4.6)a 0.95 o5
cLogD (pH 6.5)b 2.5 o5
cLogD (pH 7.4)c 3.15 o5
PSA (Å2) 34.17 o140#
FRB 7 o10$
H-bond donor 0 p5*
H-bond acceptor 5 p10*
a1A a1D 5-HT1A
LE 0.525 0.497 0.439 0.2–0.6&
LipE/LLE 6.295 5.779 4.711 –3–9&
ADME: absorption, distribution, metabolism and excretion; MW: molecular
weight; aDuodenum; bjejunum and ileum; cblood. PSA: polar surface area;
FRB: freely rotation bonds; LE: ligand efﬁciency (1.4(–logIC50)/N, where N is the
number of non-hydrogen atoms (in this case N=26); LipE/LLE: lipophilic
efﬁciency/ lipophilic ligand efﬁciency (=pIC50 – cLogP) (15,16). Note that we
used the values of Ki or KB reported previously (7) instead of IC50. *Rule of Five
(17); #(18); $(19); &(15).
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De-risking: in vitro off-target receptor binding
We decided to screen our compound for a panel of 44
targets selected based on the recommendations of re-
searchers from four major pharmaceutical companies (10)
since such a proﬁling panel (SafetyScreen 44, Euroﬁns
Cerep-Panlabs) can provide an early identiﬁcation of
signiﬁcant off-target interactions.
One way to quantify ‘‘pharmacological promiscuity’’,
i.e., the property of a compound to have pharmacological
activity at multiple targets, is to calculate the percentage of
off-targets at which the compound displayed X30%
activity at a concentration of 10 mM (20). In our case, we
did a similar analysis, but using the threshold of 50%
activity at 1 mM, in a way similar to the alternative used by
Peters et al. (20) when focusing on the more relevant
‘‘strong’’ off-target activity (deﬁned by at least 90% activity
at a concentration of 10 mM). The rationale for our pro-
posal is that both formulas are equivalent since we can
calculate that a drug with an IC50 of 1 mM for example
would exhibit both 90% activity at 10 mM and 50% activity
at 1 mM (based on the equation for a classical bimolecu-
lar reaction, i.e. using the classical ‘‘concentration-effect
relationship’’).
Of 42 BPH off-targets assayed, 7 deserved our
attention for their effect at the screening concentration.
For dopaminergic D2 and 5-HT2B receptors, only rough
estimates of Ki were possible (Table 4). For the dopa-
minergic D2 receptor, we were able to perform a whole
competition curve in our validated conditions using rat
striatum synaptosomes (12), in order to have a precise
value of Ki. In these conditions, the Ki was 0.10 mM,
around 10 times higher than the rough estimate shown in
Table 4. Due to the high afﬁnity of LDT5 for its main
therapeutic target (KB=0.18 nM, a1A-adrenoceptor), the
selectivity of LDT5 estimated by the ratio Ki off-target/Ki
a1A, and thus safety, was considered large enough for all
these 7 putative off-targets.
Preliminary safety pharmacology
Rota-rod test. As a preliminary central nervous system
(CNS) safety pharmacology, we decided to test LDT5 in
the unspeciﬁc rota-rod test, an assay that has traditionally
been used in mice and rats for motor coordination assess-
ment (22). Such test could also detect drug-induced
drowsiness such as caused by alteration of CNS dopa-
minergic D2 receptor function. Considering the time of
observation (10 min) both groups showed a similar proﬁle.
Two mice treated with LDT5 (10 mg/kg, iv) fell once, one
after 3 min and the other after 10 min of drug adminis-
tration. This did not seem different from what occurred
with the control mice. These preliminary results indicate
that LDT5 has no acute effect on mice motor coordination
when administered at a relevant dose by the iv route of
administration.
In vivo assessment of acute toxicity. We also per-
formed a preliminary assessment of acute toxicity by
observing different behavioral properties during 14 days
after a very high single dose of LDT5 (100 mg/kg ip).
Indeed, as we had no plasma exposure data (to be
obtained later), we used a dose that is 1000 times higher
than the iv ED50 for blocking the phenylephrine-induced
increase in intraurethral pressure (7). At the dose studied,
LDT5 produced no lethality neither temperature change
after 30 min (35.5±0.2°C) and 60 min administration
(35.17±0.31°C) as compared to basal (35.5±0.27°C) or
saline (35.5±0.22°C) (6 animals per condition). Further-
more, no changes in behavior were observed according to
the following parameters: state of attention care and
welfare (general appearance, irritability), motor coordina-
tion (general activity, response to touch, constriction
response of the tail, abdominal contraction, walking, and
Figure 2. Time-dependent loss of LDT5 in rat and human liver
microsomes (top) and in rat and human hepatocytes (bottom).
LDT5 (0.5 mM) was incubated in the presence of liver microsomes
(0.5 mg/mL) or hepatocytes (1 million cells/mL). Individual val-
ues were obtained from two separate experiments. The ﬁtted
curves were obtained by nonlinear regression analysis using the
ﬁrst order decay equation.
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reﬂex stiffness), muscle tone, central nervous system activ-
ity (tremors, convulsions, hyperactivity, sedation, hypnosis,
and anesthesia), the autonomic nervous system activity
(lacrimation, defecation, urination, pilo-erection, hypother-
mia, and breathing), water and food intake.
Discussion
In an attempt to mitigate the risks inherent to academic
preclinical drug discovery projects, we decided to follow
some hallmarks of the ‘‘product-oriented’’ organizations,
such as the pharmaceutical industries (11). After having
described the pharmacodynamics properties of a ﬁrst
series of N1-(2-methoxyphenyl)-N4-piperazines (6), we
then synthesized and characterized a small series of
derivatives (7). At that point, the challenge was ‘‘to select
and advance one or two compounds with properties that
are predictive of good efﬁcacy and safety in humans’’
(23). We elected one of these compounds, LDT5, as our
lead compound based on its in vitro and in vivo effects in
relevant pharmacodynamics models aiming to treat LUTS/
BPH and reduce BPH progression (7). Here we discussed
other of its properties, predictive of good pharmacoki-
netics and safety proﬁle.
When compared to target values based on successful
drugs, LDT5 offered physicochemical properties in silico
predictive of drugability, such as good oral absorption, due
to high solubility (monohydrochloride salt) and high perme-
ability (class 1 of biopharmaceutical classiﬁcation system)
(24), later conﬁrmed by experimental in vitro assays. Note
that LDT5 was transformed into a monohydrochloride salt
not only to increase its water solubility but also (mainly)
to avoid formation of N-oxides (which occurs by reaction
with oxygen from the air). This is important because the
Table 3. In vitro results of the inhibition of various cytochrome P450 isozymes by LDT5 in human liver
microsomes.
Inhibitor IC50 (mM)
CYP1A2 CYP2C9 CYP2C19 CYP2D6 CYP3A4a CYP3A4b
LDT5 4100 4100 4100 4100 4100 4100
a-Naphthoﬂavone 0.006 – – – – –
Sulfaphenazole – 0.265 – – – –
(+/-)-N-3-Benzylnirvanol – – 0.720 – – –
Quinidine – – – 0.127 – –
Ketoconazolea – – – – 0.013 –
Ketoconazoleb – – – – – 0.023
For each isozyme, a CYP-speciﬁc probe substrate was incubated along with human liver microsomes and
cofactors, and the formation of a selective metabolite was measured. The inhibitory effect of increasing the
concentration of LDT5 up to 100 mM on the production of the metabolite was determined. Standard positive
control inhibitors for each isozyme were also tested. Values of IC50 represent the inhibitor concentration
required for a 50% reduction in the measured enzyme activity. aSubstrate-midazolam; bsubstrate-
testosterone.
Table 2. In vitro results of various human CYP isozymes involvement in LDT5
metabolism.
CYP isozymes Half-life (min)
LDT5 Probe
CYP1A2 460; 460 0.8 (7-ethoxy resoruﬁn)
CYP2C9 460; 460 1.2 (diclofenac)
CYP2C19 21; 18 1.6 (omeprazole)
CYP2D6 5; 5 1.3 (dextromethorphan)
CYP3A4 54; 460 15.2 (testosterone)
The study was conducted at 0.5 mM LDT5 with 10 pM CYP and 2 mM NADPH in
phosphate buffer at 37°C. Half-lives of LDT5 and CYP speciﬁc probe substrates
used as controls were calculated from the loss of the parent compound during 1-h
incubation (see Methods). Data are indicated as individual values for the controls
and as replicates for LDT5 (separate wells in a single experiment).
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N-oxidation would prevent the protonation of the amine,
which is essential for interaction of LDT5 with the
carboxylate residue of the receptor. On the other hand,
based on a PSA target value (25) for passing the blood
brain barrier (BBB) of 90 Å2, we can expect that LDT5
would be able to cross the BBB so that de-risking for central
effects would be necessary. This expectation was further
supported by the permeability assay using MDCK-MDR1
cells indicating that LDT5 was not a substrate of P-gp. The
binding of LDT5 to human plasma proteins is not a problem
not only because it is considered as intermediate (o85%),
but also because even a high proportion of protein binding
is no longer considered as a problem since many of the
top 100 most prescribed drugs have greater than 98%
plasma protein binding (26). As a comparison, tamsulosin
has been reported (27) to bind extensively to human
plasma proteins (around 99%). The intrinsic clearance of
LDT5 in rat and human were estimated using liver
microsomes and hepatocytes, which are now considered
the gold standards (28). Intrinsic clearance reﬂects the
inherent ability of the liver to metabolize the drug, i.e., in the
absence of ﬂow limitation (29). Based on the half-lives
measured in our experiments, LDT5 was considered stable
in human liver microsomes (and hepatocytes) but unstable
in rat liver microsomes (and hepatocytes). Indeed, a
compound can be considered to be metabolically unstable
when the percent remaining at 60 min is less than 20%,
when incubated with 1 mg protein/mL of liver microsomes
(30). Such species difference is putatively due to the fact
that LDT5 is metabolized by CYP2C19 and CYP2D6 and
the substrate speciﬁcities are largely different between
human and animal isoforms for the CYP2C isozymes (31).
Such results (low intrinsic clearance in human models)
should be considered as very good for clinical transla-
tion, but some concern could arise for pharmacokinetic-
toxicokinetic studies if using rats, as usually done in drug
development programs.
With respect to the CYP phenotyping, the positive
aspects are that LDT5 is not a substrate of human
CYP3A4 and is metabolized by more than one enzyme,
properties that decrease the risk of drug-drug interaction
(DDI) in good accordance with the desirable PK proﬁle for
a drug candidate for de-risking DDI (8). On the other hand,
a negative aspect is that LDT5 is metabolized by CYP
isoforms (CYP2D6 and CYP2C19) characterized by high
genetic polymorphism, which is a concern. However, this
is not a reason for a no-go decision since there are various
examples of successful drugs that are substrates of 2C19
(e.g., citalopram, diazepam, omeprazole) or 2D6 (e.g.,
metoprolol, paroxetine). This point of view is reinforced by
the fact that the reference drug for BPH treatment,
tamsulosin, is not only extensively metabolized by CYP2D6
but also by CYP3A4 (32), the major source of drug-drug
interaction. Another important point with respect to drug







(Ki for off-targets/KB for a1A)
Off-targets
a2A 82.1 0.097 539
b1 74.0 0.198
& 1100
D2s 98.5 0.008* 44
H1 47.1 0.710 3944
5-HT2A 50.4 0.752 4178
5-HT2B 96.6 0.016* 89
5-HT transporter 54.2 0.392 2178
Estimation of selectivity was based on BPH off-targets at which LDT5 has
X50% activity at 1 mM and on the KB for the ‘‘main’’ therapeutic target (a1A-
adrenoceptor=0.18 nM) (7). Binding competition assays were performed in
duplicate with human recombinant proteins (HEK-293 cells). *As the % inhibition
was nearly maximum (plateau of the effect-concentration curve), the IC50 and
Ki presented here are only rough estimates.
#Based on theoretical calculation
performed using the equation for a classical bimolecular reaction (classical
‘‘concentration-effect relationship’’): E=EmaxCc/(EC50+Cc) where C is con-
centration and E is the inhibitory effect. The conversion of IC50 to Ki was
performed according to Cheng and Prusoff (21). $We used the ratios ‘‘Ki for off-
targets/KB for therapeutic targets’’ in order to estimate the selectivity: values
below 100 are considered putatively indicative of relevant adverse effects. &Note
that for this receptor a complete competition curve was performed to precisely
estimate the Ki value (0.21 mM), which was very close to the one estimated based
on only one concentration.
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interaction is that LDT5 did not inhibit the main human
CYPs, all tested in the present study.
It is now well recognized that assessment of the
potential adverse effects of hits is needed as early as
possible in the drug discovery process in order to reduce
safety-related attrition (10). Compounds aimed to act at an
aminergic receptor as a therapeutic target, like LDT5, are
particularly prone to pharmacological promiscuity (20),
reason why we previously estimated the binding of LDT5
to 5-HT2A and a2A-adrenoceptors, in binding assays per-
formed with rat native receptors (7). To estimate the puta-
tive adverse effects that could arise from binding at BPH
off-target receptors, we now screened LDT5 in a large
panel of 44 human receptors routinely used in four major
pharmaceutical companies (10) and calculated the ratios
‘‘Ki for off-targets/KB for therapeutic target’’ in order to
estimate the selectivity. Such approach raised concern for
only two receptors (the dopaminergic D2 and the 5-HT2B
receptors), albeit LDT5 selectivity (Ki for off-targets/Ki for
a1A) for the D2 receptor was very similar to the one of
tamsulosin (33). As we could not ﬁnd data for tamsulosin
afﬁnity for a large panel of human receptors, it was not
possible to perform a full comparison of drugs selectivity.
Even after having estimated a selective ratio of at least 40-
fold for the target a1A-adrenoceptor vs these off-target
receptors, we performed a preliminary CNS safety phar-
macology assay using the rota-rod test in mice. Although
we did not observe any effect of a single iv dose of LDT5,
we cannot rule out the risks of effects through central
dopaminergic D2 receptors such as drowsiness or motor
locomotion, since we did not investigate the drug brain
penetration and accumulation proﬁles yet. As there was a
concern with putative adverse effects through 5-HT
receptors, which play a key role in both central and
peripheral mechanisms of thermoregulation (34), we
measured mice body temperature and no alteration was
observed after administration of a high dose of LDT5
(100 mg/kg, ip). We also reported the absence of acute
toxicity after a single high dose of LDT5 (ip) since no
alteration of behavior was observed during the 14-day
period of observation.
This work highlights the drug-likeness properties and
preliminary safety proﬁle of LDT5, a compound that has
been previously selected based on in vitro and in vivo
pharmacodynamics properties aiming at oral treatment of
LUTS/BPH. We showed that LDT5 is stable in rat and
human plasma, human liver microsomes and hepato-
cytes, but unstable in rat liver microsomes and hepato-
cytes. LDT5 is highly soluble in water and permeable
across the MDCK-MDR1 monolayer, indicating good
intestinal absorption, and is not extensively bound to
plasma proteins. LDT5 is a substrate of human CYP2D6
and CYP2C19 but not of CYP3A4, did not signiﬁcantly
inﬂuence the activities of any of the human cytochrome
P450 isoforms screened and did not present any safety
concern, at least in our preliminary assays. Thus, the
present results support the further preclinical development
of LDT5 and illustrate how a public-private partnership is
important to put forward academic drug development
projects.
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